Ivermectin worthless against COVID in largest clinical trial to date

Enlarge / A box of Ivermectina medicine manufactured by Vitamedic in Brazil. (credit: Getty | SOPA Images)

The largest clinical trial to date on the use of the antiparasitic drug ivermectin against COVID-19 concluded that the drug is completely ineffective at treating the pandemic disease, according to results published in The New England Journal of Medicine on Wednesday.

The double-blind, randomized, placebo-controlled clinical trial was primarily designed to test if ivermectin could reduce the need for hospitalization among 1,358 COVID-19 patients at high risk of severe disease. Ivermectin did not, according to the international team of researchers behind the trial, dubbed TOGETHER. "We did not find a significantly or clinically meaningful lower risk of medical admission to a hospital or prolonged emergency department observation with ivermectin," the researchers reported.

Covid-19 Coverage

• Ivermectin worthless against COVID in largest clinical trial to date
• Pfizer, Moderna vaccines aren't the same; study finds antibody differences
• With a second booster now authorized for some, the question is when to get it [Updated]
• Shanghai in lockdown as officials work to test all 26M residents
• Omicron is trouncing the argument for natural immunity" to COVID

View more storiesThe folks with TOGETHER also found that the drug failed to reduce all other secondary outcomes of COVID-19, including the time to recovery, time to viral clearance on PCR test, time spent in the hospital, the need for mechanical ventilation, the duration of mechanical ventilation, death, or the time to death. "We found no important effects of treatment with ivermectin on the secondary outcomes," the researchers wrote.

Read 9 remaining paragraphs | Comments